Morphological assessment of the biological effects of eldecalcitol.
Morphological assessment of the biological effects of eldecalcitol.
复制标题
艾德骨化醇生物效应的形态学评估。
DOI:
10.1007/978-981-16-5613-2_27
复制
发表时间:
2021
期刊:
影响因子:
--
通讯作者:
Amizuka N.
中科院分区:
文献类型:
--
作者:
Hasegawa T.;Hongo H.;Yamamoto T.;Amizuka N.
Therapeutic drugs for osteoporotic patients can be divided into anti-resorptive or anabolic reagents. Eldecalcitol, an analog of active vitamin D3, has been developed in Japan and provides more anti-resorptive effects compared to alfacalcidol—a predrug of eldecalcitol. The anti-resorptive effects of eldecalcitol are reportedly related to the reduced population of preosteoblasts that support osteoclastogenesis, diminished expression of RANKL, and suppressed sphingosine-1-phosphate receptor 2 in circulating osteoclast precursors. Conversely, during the last decade, eldecalcitol has been shown to induce the modeling-based bone formation in trabeculae, i.e.,“minimodeling” previously proposed by Frost, in addition to exerting anti-resorptive effects for the osteoporotic treatment. Minimodeling-/modeling-based bone formation is not dependent on foregoing osteoclastic bone resorption; resting osteoblasts, also referred to as bone lining cells, would be activated to deposit new bone on the existing bone. Eldecalcitol-driven minimodeling-/modeling-based bone formation can be seen not only in rodents but also in primates and human patients. Since minimodeling-/modeling-based bone formation is not coupled with osteoclastic bone resorption, eldecalcitol may be able to induce bidirectional function—anti-resorptive effects and anabolic effects mediated by minimodeling-/modeling-based bone formation. In this chapter, studies on the biological effects of eldecalcitol will be introduced.